Working… Menu

Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00027391
Recruitment Status : Completed
First Posted : December 7, 2001
Last Update Posted : March 25, 2015
Information provided by:
FDA Office of Orphan Products Development

Brief Summary:
This is a study to determine whether albuterol or oxandrolone, alone or in combination, are able to increase strength and muscle mass in patients with FSHD. It also will determine if albuterol given in "pulsed" fashion will have more effect than when given continuously.

Condition or disease Intervention/treatment Phase
Muscular Dystrophies Drug: Albuterol Drug: Oxandrolone Not Applicable

Detailed Description:
Patients will be randomized to 1 of 4 groups: placebo, pulsed albuterol, oxandrolone, or both pulsed albuterol and oxandrolone. Treatment will continue for 52 weeks unless unacceptable side effects occur. Patients will undergo testing of muscle function. All patients will return for follow-up assessments at Weeks 4, 12, 26, and 52.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 160 participants
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Official Title: Clinical Trials of Albuterol and Oxandrolone in FSH Dystrophy
Study Start Date : September 2001
Study Completion Date : August 2004

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Presence of 4q35 "small fragment" of less than 40 kb by standard DNA testing
  • Weakness of the facial muscles, including frontalis, orbicularis oculi, or orbicularis oris
  • Weakness of scapular stabilizers or foot dorsiflexors
  • Ambulatory
  • Weakness grade 2 or worse in the arm using upper extremity grading scale

Exclusion criteria:

  • Prior use of oral beta-2 agonists for a period of at least 1 year or within the past 3 months
  • Concurrent use of other sympathomimetic agents, antidepressants, or beta-2 receptor blockers
  • Pregnancy
  • Known hypersensitivity to anabolic steroids
  • Any medical or psychological condition that would interfere with the study
  • Requirement for a wheelchair

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00027391

Layout table for location information
United States, Ohio
Ohio State University Medical Center
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
FDA Office of Orphan Products Development
Layout table for investigator information
Principal Investigator: John T. Kissel, M.D. Ohio State University
Layout table for additonal information Identifier: NCT00027391    
Other Study ID Numbers: FD-R-2029-01
First Posted: December 7, 2001    Key Record Dates
Last Update Posted: March 25, 2015
Last Verified: November 2001
Keywords provided by FDA Office of Orphan Products Development:
Muscle Weakness, Muscular Dystrophy
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Anabolic Agents